46例瑞舒伐他汀以及阿托伐他汀用于冠心病的疗效和安全性观察

Observation on 46 Cases of Coronary Heart Disease With Rosuvastatin and Atorvastatin

目的：探讨、分析瑞舒伐他汀以及阿托伐他汀用于冠心病临床治疗效果和安全性。方法选取我院2013年3月～2014年3月收治的46例冠心病的患者，并随机分成两组，分别给予等同剂量的瑞舒伐他汀（实验组）以及阿托伐他汀（对照组）进行口服治疗，详细记录两组患者治疗过程中的数据，并进行为期3周的治疗。结果在经过治疗后，实验组总有效率为91.3%，对照组总有效率为78.2%，两组患者的血清总胆固醇、低密度脂蛋白胆固醇以及三酰甘油均比治疗前低，且其血脂水平改善程度优于对照组患者，且差异有统计学意义。结论在同等剂量的情况下，瑞舒伐他汀对比于阿托伐他汀，其治疗效果以及安全性均较好。

Objective To investigate and analysis the clinical therapeutic effect and safety of rosuvastatin and atorvastatin to treat coronary heart disease. Methods 46 patients with coronary heart disease （CHD） from March 2013 to March 2014 in our hospital were randomly divided into two groups respectively, they were given equivalent doses of rosuvastatin （experimental group） and atorvastatin oral treatment （control group）, recorded the data in the process of two groups of patients, and treated for 3 weeks. Results After treatment, the total effective rate in the experimental group was 91.3%, total effective rate in control group was 78.2%, two groups of patients with serum total cholesterol, low density lipoprotein cholesterol, and three acyl glycerol were lower than before, and the improvement of blood lipid level was better than the control group, and with statistically signiifcant. Conclusion Under the condition of the same dose, therapeutic effect and safety of rosuvastatin are higher than atorvastatin.